Eli Lilly and Company (NYSE:LLY) Shares Sold by WorthPointe LLC

WorthPointe LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 451 shares of the company’s stock after selling 18 shares during the quarter. WorthPointe LLC’s holdings in Eli Lilly and Company were worth $348,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Heritage Wealth Management Inc. CA lifted its position in Eli Lilly and Company by 19.9% during the 4th quarter. Heritage Wealth Management Inc. CA now owns 1,049 shares of the company’s stock worth $810,000 after acquiring an additional 174 shares in the last quarter. Zions Bancorporation N.A. lifted its position in shares of Eli Lilly and Company by 26.8% during the fourth quarter. Zions Bancorporation N.A. now owns 11,826 shares of the company’s stock worth $9,130,000 after purchasing an additional 2,496 shares in the last quarter. TIAA Trust National Association boosted its stake in shares of Eli Lilly and Company by 8.6% in the fourth quarter. TIAA Trust National Association now owns 93,364 shares of the company’s stock valued at $72,077,000 after purchasing an additional 7,393 shares during the period. Princeton Capital Management LLC grew its holdings in Eli Lilly and Company by 3.3% during the 4th quarter. Princeton Capital Management LLC now owns 15,402 shares of the company’s stock valued at $11,890,000 after purchasing an additional 496 shares in the last quarter. Finally, EFG Asset Management North America Corp. purchased a new stake in Eli Lilly and Company during the 4th quarter worth $2,599,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on LLY. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Citigroup lowered their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Truist Financial lifted their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Morgan Stanley set a $1,146.00 target price on Eli Lilly and Company in a research note on Thursday, March 6th. Finally, Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,009.72.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $865.94 on Tuesday. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The firm’s 50-day moving average price is $837.36 and its two-hundred day moving average price is $837.97. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The stock has a market capitalization of $821.06 billion, a P/E ratio of 73.95, a P/E/G ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company declared that its board has approved a stock repurchase program on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.